Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.12 EUR | +1.63% | +1.30% | -16.58% |
Mar. 27 | Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment | MT |
Mar. 25 | Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024 |
Sales 2024 * | 11.5M 12.39M | Sales 2025 * | 15M 16.16M | Capitalization | 145M 157M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 12.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.69 x |
P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-24
x | Employees | 101 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 16.94% |
Latest transcript on Heidelberg Pharma AG
1 day | +1.63% | ||
1 week | +1.30% | ||
Current month | +1.96% | ||
1 month | +2.30% | ||
3 months | -14.75% | ||
6 months | -8.50% | ||
Current year | -16.58% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Pahl
CEO | Chief Executive Officer | - | 11-12-31 |
Walter Miller
DFI | Director of Finance/CFO | - | 23-04-30 |
András Strassz
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 05-04-28 | |
Georg F. Baur
BRD | Director/Board Member | 74 | 00-12-13 |
Birgit Kudlek
BRD | Director/Board Member | 57 | 12-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 3.12 | +1.63% | 11,623 |
24-03-27 | 3.07 | +0.66% | 16,717 |
24-03-26 | 3.05 | -1.61% | 5,980 |
24-03-25 | 3.1 | +0.32% | 31,880 |
24-03-22 | 3.09 | +0.32% | 19,122 |
Delayed Quote Xetra, March 28, 2024 at 12:36 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.58% | 157M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |